This study investigates pancreatic cancer. It evaluates delivering chemotherapy using an implantable device directly to the pancreas.
The study evaluates the safety and tolerability of this method. It also examines the amount of chemotherapy in the blood and the tumor's response.
- Who can participate: Adults with nonmetastatic, nonresectable pancreatic cancer and an ECOG status of 0 or 1 may participate. Participants should have received prior neoadjuvant chemotherapy.
- Study details: Participants will have a device placed on their pancreas and receive treatment. Some will receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.
- Study timelines: The study will last 24 weeks.